Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunitybio Inc (NQ: IBRX )

3.400 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,937
Open 3.400
Bid (Size) 3.420 (1)
Ask (Size) 3.480 (12)
Prev. Close 3.400
Today's Range 3.400 - 3.400
52wk Range 1.250 - 10.53
Shares Outstanding 391,156,513
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
Via Benzinga

Performance

YTD
-35.11%
-35.11%
1 Month
-8.11%
-8.11%
3 Month
-46.54%
-46.54%
6 Month
-39.50%
-39.50%
1 Year
+144.60%
+144.60%

More News

Read More
ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer
From ImmunityBio, Inc.
Via Business Wire
How Is The Market Feeling About ImmunityBio?
Via Benzinga
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Top 3 Health Care Stocks That Are Set To Fly This Quarter
Via Benzinga
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
IBRX Stock Earnings: ImmunityBio Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer
From ImmunityBio, Inc.
Via Business Wire
IMMUNITYBIO INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ImmunityBio, Inc. - IBRX
From Kahn Swick & Foti, LLC
Via Business Wire
7 Biotech Stocks to Keep on Your Clinical Radar
Via InvestorPlace
3 Top Cancer Treatment Stocks to Buy Now
Via InvestorPlace
China's Bilibili And Ollie's Bargain Outlet Were Among 10 Mid Cap Stocks With Biggest Gains In The Last Week (June 16-June 22, 2024): Are They In Your Portfolio?
Via Benzinga
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why ImmunityBio Stock Is Trading Higher Thursday
Via Benzinga
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
Via Benzinga
ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors
From ImmunityBio, Inc.
Via Business Wire
3 Short-Squeeze Stocks Outwitting the Pessimistic Predictions
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
From ImmunityBio, Inc.
Via Business Wire
These 3 Interesting Stocks Are Seeing Heavy Short Interest In June 2024
Via Talk Markets
Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
From ImmunityBio, Inc.
Via Business Wire
Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months
Via Talk Markets
IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Diversified Communications
© 2023 Diversified Communications. All rights reserved.